Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/LGR5_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/LGR5_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/LGR5_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/LGR5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/LGR5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/LGR5_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00085447 | Endometrium | AEH | epidermis development | 52/2100 | 324/18723 | 5.00e-03 | 3.14e-02 | 52 |
GO:003011113 | Endometrium | EEC | regulation of Wnt signaling pathway | 74/2168 | 328/18723 | 1.03e-08 | 6.47e-07 | 74 |
GO:001605513 | Endometrium | EEC | Wnt signaling pathway | 90/2168 | 444/18723 | 6.65e-08 | 3.50e-06 | 90 |
GO:019873813 | Endometrium | EEC | cell-cell signaling by wnt | 90/2168 | 446/18723 | 8.25e-08 | 4.23e-06 | 90 |
GO:006082813 | Endometrium | EEC | regulation of canonical Wnt signaling pathway | 56/2168 | 253/18723 | 1.18e-06 | 3.90e-05 | 56 |
GO:000165512 | Endometrium | EEC | urogenital system development | 69/2168 | 338/18723 | 1.70e-06 | 5.18e-05 | 69 |
GO:007200112 | Endometrium | EEC | renal system development | 63/2168 | 302/18723 | 2.24e-06 | 6.59e-05 | 63 |
GO:005067315 | Endometrium | EEC | epithelial cell proliferation | 83/2168 | 437/18723 | 3.38e-06 | 9.14e-05 | 83 |
GO:006007013 | Endometrium | EEC | canonical Wnt signaling pathway | 61/2168 | 303/18723 | 1.05e-05 | 2.25e-04 | 61 |
GO:006056213 | Endometrium | EEC | epithelial tube morphogenesis | 64/2168 | 325/18723 | 1.35e-05 | 2.70e-04 | 64 |
GO:003017713 | Endometrium | EEC | positive regulation of Wnt signaling pathway | 34/2168 | 140/18723 | 1.89e-05 | 3.50e-04 | 34 |
GO:009026313 | Endometrium | EEC | positive regulation of canonical Wnt signaling pathway | 26/2168 | 106/18723 | 1.46e-04 | 1.87e-03 | 26 |
GO:000975513 | Endometrium | EEC | hormone-mediated signaling pathway | 38/2168 | 190/18723 | 5.18e-04 | 5.21e-03 | 38 |
GO:006132611 | Endometrium | EEC | renal tubule development | 21/2168 | 94/18723 | 2.18e-03 | 1.63e-02 | 21 |
GO:004358814 | Endometrium | EEC | skin development | 45/2168 | 263/18723 | 4.69e-03 | 2.99e-02 | 45 |
GO:00613331 | Endometrium | EEC | renal tubule morphogenesis | 17/2168 | 75/18723 | 4.71e-03 | 2.99e-02 | 17 |
GO:000854414 | Endometrium | EEC | epidermis development | 53/2168 | 324/18723 | 5.92e-03 | 3.54e-02 | 53 |
GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
GO:00435888 | Esophagus | ESCC | skin development | 163/8552 | 263/18723 | 6.48e-08 | 1.14e-06 | 163 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LGR5 | SNV | Missense_Mutation | | c.2579N>G | p.Gln860Arg | p.Q860R | O75473 | protein_coding | tolerated(0.1) | benign(0.001) | TCGA-A2-A4RW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
LGR5 | SNV | Missense_Mutation | | c.2523N>T | p.Trp841Cys | p.W841C | O75473 | protein_coding | tolerated(0.07) | benign(0.005) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
LGR5 | SNV | Missense_Mutation | novel | c.2662N>A | p.Pro888Thr | p.P888T | O75473 | protein_coding | deleterious(0.01) | benign(0.024) | TCGA-B6-A400-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
LGR5 | SNV | Missense_Mutation | | c.1567N>C | p.Glu523Gln | p.E523Q | O75473 | protein_coding | deleterious(0.04) | possibly_damaging(0.616) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
LGR5 | SNV | Missense_Mutation | rs779176913 | c.185N>G | p.Ser62Cys | p.S62C | O75473 | protein_coding | deleterious(0.02) | possibly_damaging(0.781) | TCGA-BH-A8FZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LGR5 | SNV | Missense_Mutation | novel | c.1115N>C | p.Val372Ala | p.V372A | O75473 | protein_coding | tolerated(0.44) | benign(0.001) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | | SD |
LGR5 | insertion | Frame_Shift_Ins | novel | c.1196_1197insAAAGTTGAGAAACATAGATAATATTATTTTTT | p.Ser399ArgfsTer16 | p.S399Rfs*16 | O75473 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LGR5 | insertion | In_Frame_Ins | novel | c.279_280insTTCTGCTTAAAGTGGCTTGTTGTTTCCTGTGCCAGGAACTACTGT | p.Glu93_Glu94insPheCysLeuLysTrpLeuValValSerCysAlaArgAsnTyrCys | p.E93_E94insFCLKWLVVSCARNYC | O75473 | protein_coding | | | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LGR5 | deletion | Frame_Shift_Del | novel | c.82delN | p.Gly28ValfsTer4 | p.G28Vfs*4 | O75473 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
LGR5 | SNV | Missense_Mutation | | c.1360C>G | p.His454Asp | p.H454D | O75473 | protein_coding | tolerated(0.23) | benign(0.028) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8549 | LGR5 | G PROTEIN COUPLED RECEPTOR, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | fluorouracil | FLUOROURACIL | 25665511 |
8549 | LGR5 | G PROTEIN COUPLED RECEPTOR, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | agonist | 178100588 | | |
8549 | LGR5 | G PROTEIN COUPLED RECEPTOR, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | agonist | 178100587 | | |
8549 | LGR5 | G PROTEIN COUPLED RECEPTOR, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | agonist | 178100586 | | |
8549 | LGR5 | G PROTEIN COUPLED RECEPTOR, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | agonist | 178100589 | | |